Medannex Ltd
Medannex is pioneering the targeting of annexin-A1 to provide powerful new treatment options for people impacted by cancers and autoimmune diseases. Annexin-A1 drives cancer cell growth and migration and also plays a key role in the development of several autoimmune conditions. Extensive pre-clinical data demonstrate that our first-in-class monoclonal antibody therapeutic (MDX-124) effectively blocks the action of annexin-A1. A Phase 1b clinical study is under way, in cancer patients. In parallel, we are currently preparing for further clinical studies in autoimmune diseases.
7-day free trial · no credit card
Verified contacts
6
available on Kipplo
LinkedIn employees
11
11 to 50 range
Open roles
—
no listings
Distinct roles
4
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 6 verified contacts at Medannex Ltd
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
6 contacts with verified email or phone · masked until revealed.
- CT
Colin Tennant
Project Director · Science
EmailPhone - PF
Paul Flook
Financial Controller · Finance & Accounting
EmailPhone - IA
Ian Abercrombie
Chief Executive Officer · General Business & Management
EmailPhone
Showing 3 of 6 verified contacts
Top roles at Medannex Ltd
4 distinct titles indexed · top 4 shown.
- 2chief executive officer
- 1financial controller
- 1project director
- 1research and development intern
Sign up to unlock all 6 contacts at Medannex Ltd
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 6 verified contacts at Medannex Ltd
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.